{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:29:45Z","timestamp":1788236985355,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Umea University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Qual Life Res"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>As genetic testing becomes increasingly integrated into routine care, understanding its impact on psychological well-being and health-related quality of life (HRQoL) is essential. This study assessed HRQoL, anxiety and cancer worry following hereditary cancer testing in a Swedish clinical setting and identified predictors of these outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Participants were recruited from four outpatient cancer genetics clinics across Sweden. Eligible individuals either carried a pathogenic variant or met clinical criteria for familial breast or colorectal cancer. Questionnaires were completed shortly after receiving test results and again 6 months later. HRQoL was measured using the RAND-36, anxiety using the State-Trait Anxiety Inventory and cancer worry using the Cancer Worry Scale. Outcomes were compared with age- and sex-adjusted Swedish population data. Predictors of outcomes were analysed using multivariable linear regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 254 participants completed at least one questionnaire. HRQoL improved across all domains over 6 months, while anxiety and cancer worry declined. Participants without a recent cancer diagnosis had scores close to population norms at both time points. Those diagnosed within the previous year had lower HRQoL and higher anxiety and cancer worry, although they improved over time. Poorer outcomes were linked to a recent cancer diagnosis, being an index case, female sex and younger age, while education level and the test result itself were not associated with worse results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Genetic testing was not associated with substantial short- or medium-term negative effects on HRQoL, anxiety or cancer worry. Individual risk factors should be considered when offering psychosocial support.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Plain English summary<\/jats:title>\n                    <jats:p>Genetic testing is becoming more widely used, but earlier research on how testing affects everyday life often involved small groups or older data. Testing is also used in new ways today, which creates a need for updated studies to understand people\u2019s experiences and to see who might need extra support. In this study, we examined quality of life, anxiety and cancer-related worry in people tested for hereditary breast, ovarian or colorectal cancer. They completed questionnaires shortly after receiving their results and again 6 months later. We compared their answers with those from the general Swedish population. Quality of life improved over time, and anxiety and cancer worry decreased. People without a recent cancer diagnosis had scores similar to population norms. Those with a recent diagnosis had lower scores but also improved. Younger people, women and those recently diagnosed with cancer reported more anxiety and worry and lower quality of life scores. Education level and the test result itself did not affect these outcomes. Overall, genetic testing did not appear to cause lasting negative effects. Support may be most helpful for people with these risk factors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11136-026-04184-1","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T09:38:57Z","timestamp":1770889137000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Quality of life, anxiety and cancer worry following hereditary cancer testing: a 6-month Swedish follow-up study"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1301-9360","authenticated-orcid":false,"given":"Ylva","family":"Heyman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"R\u00f6jlar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2218-6881","authenticated-orcid":false,"given":"Carolina","family":"Hawranek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2618-7358","authenticated-orcid":false,"given":"Barbro","family":"Numan Hellquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2441-2395","authenticated-orcid":false,"given":"Anna","family":"Ros\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"issue":"23","key":"4184_CR1","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker, K. B., Hopper, J. L., Barnes, D. R., Phillips, K. A., Mooij, T. M., & Roos-Blom, M. J. (2017). Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA, 317(23), 2402\u20132416.","journal-title":"JAMA"},{"issue":"7","key":"4184_CR2","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1136\/gutjnl-2017-314057","volume":"67","author":"P M\u00f8ller","year":"2018","unstructured":"M\u00f8ller, P., Sepp\u00e4l\u00e4, T. T., Bernstein, I., Holinski-Feder, E., Sala, P., & Gareth Evans, D. (2018). Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut, 67(7), 1306\u20131316.","journal-title":"Gut"},{"issue":"5","key":"4184_CR3","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/bjs.11902","volume":"108","author":"T. T. Sepp\u00e4l\u00e4","year":"2021","unstructured":"Sepp\u00e4l\u00e4, T. T., Latchford, A., Negoi, I., Sampaio Soares, A., Jimenez-Rodriguez, R., & S\u00e1nchez-Guill\u00e9n, L. (2021). European guidelines from the EHTG and ESCP for Lynch syndrome: An updated third edition of the Mallorca guidelines based on gene and gender. British Journal of Surgery, 108(5), 484\u2013498.","journal-title":"British Journal of Surgery"},{"issue":"3","key":"4184_CR4","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1136\/gutjnl-2019-319915","volume":"69","author":"KJ Monahan","year":"2020","unstructured":"Monahan, K. J., Bradshaw, N., Dolwani, S., Desouza, B., Dunlop, M. G., & East, J. E. (2020). Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)\/Association of Coloproctology of Great Britain and Ireland (ACPGBI)\/United Kingdom Cancer Genetics Group (UKCGG). Gut, 69(3), 411\u2013444.","journal-title":"Gut"},{"issue":"1","key":"4184_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.annonc.2022.10.004","volume":"34","author":"C Sessa","year":"2023","unstructured":"Sessa, C., Balma\u00f1a, J., Bober, S. L., Cardoso, M. J., Colombo, N., Curigliano, G., et al. (2023). Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO clinical practice guideline. Annals of Oncology, 34(1), 33\u201347.","journal-title":"Annals of Oncology"},{"issue":"4","key":"4184_CR6","doi-asserted-by":"publisher","first-page":"3590","DOI":"10.3390\/curroncol30040274","volume":"30","author":"A Isselhard","year":"2023","unstructured":"Isselhard, A., Lautz, Z., Rhiem, K., & Stock, S. (2023). Assessing psychological morbidity in cancer-unaffected BRCA1\/2 pathogenic variant carriers: A systematic review. Current Oncology, 30(4), 3590\u20133608.","journal-title":"Current Oncology"},{"issue":"5","key":"4184_CR7","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1007\/s10897-016-9949-6","volume":"25","author":"J Ringwald","year":"2016","unstructured":"Ringwald, J., Wochnowski, C., Bosse, K., Giel, K. E., Sch\u00e4ffeler, N., Zipfel, S., et al. (2016). Psychological distress, anxiety, and depression of cancer-affected BRCA1\/2 mutation carriers: A systematic review. Journal of Genetic Counseling, 25(5), 880\u2013891.","journal-title":"Journal of Genetic Counseling"},{"issue":"8","key":"4184_CR8","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1007\/s10620-015-3626-8","volume":"60","author":"P Galiatsatos","year":"2015","unstructured":"Galiatsatos, P., Rothenmund, H., Aubin, S., & Foulkes, W. D. (2015). Psychosocial impact of lynch syndrome on affected individuals and families. Digestive Diseases and Sciences, 60(8), 2246\u20132250.","journal-title":"Digestive Diseases and Sciences"},{"issue":"2","key":"4184_CR9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s12160-008-9060-9","volume":"36","author":"TM Beran","year":"2008","unstructured":"Beran, T. M., Stanton, A. L., Kwan, L., Seldon, J., Bower, J. E., & Vodermaier, A. (2008). The trajectory of psychological impact in BRCA1\/2 genetic testing: Does time heal? Annals of Behavioral Medicine, 36(2), 107\u2013116.","journal-title":"Annals of Behavioral Medicine."},{"issue":"6","key":"4184_CR10","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/j.1399-0004.2004.00339.x","volume":"66","author":"B Meiser","year":"2004","unstructured":"Meiser, B., Collins, V., Warren, R., Gaff, C., St John, D. J. B., Young, M. A., & Halliday, J. (2004). Psychological impact of genetic testing for hereditary non-polyposis colorectal cancer. Clinical Genetics, 66(6), 502\u2013511.","journal-title":"Clinical Genetics"},{"issue":"3","key":"4184_CR11","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s10897-010-9344-7","volume":"20","author":"TE Power","year":"2011","unstructured":"Power, T. E., Robinson, J. W., Bridge, P., Bernier, F. P., & Gilchrist, D. M. (2011). Distress and psychosocial needs of a heterogeneous high risk familial cancer population. Journal of Genetic Counseling, 20(3), 249\u2013269.","journal-title":"Journal of Genetic Counseling"},{"issue":"6","key":"4184_CR12","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.breast.2012.02.004","volume":"21","author":"N Bosch","year":"2012","unstructured":"Bosch, N., Junyent, N., Gadea, N., Brunet, J., y Cajal, T. R., Torres, A., & Balma\u00f1a, J. (2012). What factors may influence psychological well being at three months and one year post BRCA genetic result disclosure? The Breast, 21(6), 755\u2013760.","journal-title":"The Breast"},{"issue":"2","key":"4184_CR13","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1023\/B:FAME.0000039863.89137.f9","volume":"3","author":"B Arver","year":"2004","unstructured":"Arver, B., Haegermark, A., Platten, U., Lindblom, A., & Brandberg, Y. (2004). Evaluation of psychosocial effects of pre-symptomatic testing for breast\/ovarian and colon cancer pre-disposing genes: A 12-month follow-up. Familial Cancer, 3(2), 109\u2013116.","journal-title":"Familial Cancer"},{"issue":"1","key":"4184_CR14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ejca.2006.08.023","volume":"43","author":"I van Oostrom","year":"2007","unstructured":"van Oostrom, I., Meijers-Heijboer, H., Duivenvoorden, H. J., Br\u00f6cker-Vriends, A. H., van Asperen, C. J., Sijmons, R. H., & Tibben, A. (2007). Prognostic factors for hereditary cancer distress six months after BRCA1\/2 or HNPCC genetic susceptibility testing. European Journal of Cancer, 43(1), 71\u201377.","journal-title":"European Journal of Cancer"},{"issue":"8","key":"4184_CR15","doi-asserted-by":"publisher","first-page":"368","DOI":"10.5694\/mja2.51906","volume":"218","author":"DL De Silva","year":"2023","unstructured":"De Silva, D. L., Stafford, L., Skandarajah, A. R., Sinclair, M., Devereux, L., Hogg, K., & Lindeman, G. J. (2023). Universal genetic testing for women with newly diagnosed breast cancer in the context of multidisciplinary team care. Medical Journal of Australia, 218(8), 368\u2013373.","journal-title":"Medical Journal of Australia"},{"issue":"5","key":"4184_CR16","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s10897-005-1371-4","volume":"14","author":"E Claes","year":"2005","unstructured":"Claes, E., Evers-Kiebooms, G., Denayer, L., Decruyenaere, M., Boogaerts, A., Philippe, K., et al. (2005). Predictive genetic testing for hereditary breast and ovarian cancer: Psychological distress and illness representations 1 year following disclosure. Journal of Genetic Counseling, 14(5), 349\u2013363.","journal-title":"Journal of Genetic Counseling"},{"issue":"5","key":"4184_CR17","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/sj.bjc.6603610","volume":"96","author":"C Foster","year":"2007","unstructured":"Foster, C., Watson, M., Eeles, R., Eccles, D., Ashley, S., Davidson, R., & Evans, D. G. R. (2007). Predictive genetic testing for BRCA1\/2 in a UK clinical cohort: Three-year follow-up. British Journal of Cancer, 96(5), 718\u2013724.","journal-title":"British Journal of Cancer"},{"issue":"6","key":"4184_CR18","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/ejhg.2015.196","volume":"24","author":"H H\u00f8berg-Vetti","year":"2016","unstructured":"H\u00f8berg-Vetti, H., Bjorvatn, C., Fiane, B. E., Aas, T., Woie, K., Espelid, H., & Hoogerbrugge, N. (2016). BRCA1\/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: The DNA-BONus study. European Journal of Human Genetics, 24(6), 881\u2013888.","journal-title":"European Journal of Human Genetics"},{"issue":"5","key":"4184_CR19","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1097\/GIM.0b013e31804b45db","volume":"9","author":"VR Collins","year":"2007","unstructured":"Collins, V. R., Meiser, B., Ukoumunne, O. C., Gaff, C., St John, D. J., & Halliday, J. L. (2007). The impact of predictive genetic testing for hereditary nonpolyposis colorectal cancer: Three years after testing. Genetics in Medicine, 9(5), 290\u2013297.","journal-title":"Genetics in Medicine"},{"issue":"1","key":"4184_CR20","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1186\/s13063-023-07829-5","volume":"24","author":"C Hawranek","year":"2023","unstructured":"Hawranek, C., Ehrencrona, H., \u00d6fverholm, A., Hellquist, B. N., & Ros\u00e9n, A. (2023). Direct letters to relatives at risk of hereditary cancer-study protocol for a multi-center randomized controlled trial of healthcare-assisted versus family-mediated risk disclosure at Swedish cancer genetics clinics (DIRECT-study). Trials, 24(1), 810.","journal-title":"Trials"},{"issue":"10","key":"4184_CR21","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1038\/s41431-025-01922-w","volume":"33","author":"H Ehrencrona","year":"2025","unstructured":"Ehrencrona, H., \u00d6fverholm, A., Hawranek, C., Lovmar, L., Svensson, S., Wennstedt, S., & Ros\u00e9n, A. (2025). Direct letters to relatives at risk of hereditary cancer\u2014a randomised trial on healthcare-assisted versus family-mediated risk disclosure. European Journal of Human Genetics, 33(10), 1359\u20131367.","journal-title":"European Journal of Human Genetics"},{"issue":"6","key":"4184_CR22","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware Jr","year":"1992","unstructured":"Ware, J. E., Jr., & Sherbourne, C. D. (1992). The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Medical Care, 30(6), 473\u2013483.","journal-title":"Medical Care"},{"key":"4184_CR23","unstructured":"Spielberger, C. D., Gorsuch, R. L., & Lushene, R. E. (1970). STAI Manual for the State-trait Anxiety Inventory (Self-evaluation Questionnaire): Consulting Psychologists Press."},{"issue":"4","key":"4184_CR24","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1200\/JCO.1994.12.4.843","volume":"12","author":"C Lerman","year":"1994","unstructured":"Lerman, C., Daly, M., Masny, A., & Balshem, A. (1994). Attitudes about genetic testing for breast-ovarian cancer susceptibility. Journal of Clinical Oncology, 12(4), 843\u2013850.","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"4184_CR25","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/0277-9536(95)00125-Q","volume":"41","author":"M Sullivan","year":"1995","unstructured":"Sullivan, M., Karlsson, J., & Ware, J. E., Jr. (1995). The Swedish SF-36 Health Survey\u2014I. Evaluation of data quality, scaling assumptions, reliability and construct validity across general populations in Sweden. Social science and medicine, 41(10), 1349\u20131358.","journal-title":"Social science and medicine"},{"issue":"1","key":"4184_CR26","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s41687-018-0030-0","volume":"2","author":"L Orwelius","year":"2018","unstructured":"Orwelius, L., Nilsson, M., Nilsson, E., Wenemark, M., Walfridsson, U., Lundstr\u00f6m, M., & Kristenson, M. (2018). The Swedish RAND-36 Health Survey-reliability and responsiveness assessed in patient populations using Svensson\u2019s method for paired ordinal data. Journal of Patient-reported Outcomes, 2(1), 4.","journal-title":"Journal of Patient-reported Outcomes"},{"issue":"1","key":"4184_CR27","doi-asserted-by":"publisher","first-page":"101","DOI":"10.4321\/S1135-57272014000100007","volume":"88","author":"A Guill\u00e9n-Riquelme","year":"2014","unstructured":"Guill\u00e9n-Riquelme, A., & Buela-Casal, G. (2014). Meta-analysis of group comparison and meta-analysis of reliability generalization of the state-trait anxiety inventory Questionnaire (STAI). Revista Espa\u00f1ola de Salud P\u00fablica, 88(1), 101\u2013112.","journal-title":"Revista Espa\u00f1ola de Salud P\u00fablica"},{"issue":"5","key":"4184_CR28","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/BF00449430","volume":"2","author":"C Forsberg","year":"1993","unstructured":"Forsberg, C., & Bj\u00f6rvell, H. (1993). Swedish population norms for the GHRI, HI and STAI-state. Quality of Life Research, 2(5), 349\u2013356.","journal-title":"Quality of Life Research"},{"issue":"4","key":"4184_CR29","doi-asserted-by":"publisher","first-page":"918","DOI":"10.3390\/cancers14040918","volume":"14","author":"C Hawranek","year":"2022","unstructured":"Hawranek, C., Maxon, J., Andersson, A., Van Guelpen, B., Hajdarevic, S., NumanHellquist, B., & Ros\u00e9n, A. (2022). Cancer worry distribution and willingness to undergo colonoscopy at three levels of hypothetical cancer risk\u2014a population-based survey in Sweden. Cancers, 14(4), 918. https:\/\/doi.org\/10.3390\/cancers14040918","journal-title":"Cancers"},{"issue":"11","key":"4184_CR30","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1002\/pon.4782","volume":"27","author":"JAE Custers","year":"2018","unstructured":"Custers, J. A. E., Kwakkenbos, L., van de Wal, M., Prins, J. B., & Thewes, B. (2018). Re-validation and screening capacity of the 6-item version of the cancer worry scale. Psycho-Oncology, 27(11), 2609\u20132615.","journal-title":"Psycho-Oncology"},{"issue":"1","key":"4184_CR31","doi-asserted-by":"publisher","first-page":"E44","DOI":"10.1097\/NCC.0b013e3182813a17","volume":"37","author":"JA Custers","year":"2014","unstructured":"Custers, J. A., van den Berg, S. W., van Laarhoven, H. W., Bleiker, E. M., Gielissen, M. F., & Prins, J. B. (2014). The cancer worry scale: Detecting fear of recurrence in breast cancer survivors. Cancer Nursing, 37(1), E44-50.","journal-title":"Cancer Nursing"},{"issue":"4","key":"4184_CR32","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/NCC.0000000000000511","volume":"41","author":"A Caruso","year":"2018","unstructured":"Caruso, A., Vigna, C., & Gremigni, P. (2018). The cancer worry scale revised for breast cancer genetic counseling. Cancer Nursing, 41(4), 311\u2013319.","journal-title":"Cancer Nursing"},{"issue":"1","key":"4184_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-021-00331-z","volume":"5","author":"E Ohlsson-Nevo","year":"2021","unstructured":"Ohlsson-Nevo, E., Hiyoshi, A., Nor\u00e9n, P., M\u00f6ller, M., & Karlsson, J. (2021). The Swedish RAND-36: Psychometric characteristics and reference data from the Mid-Swed Health Survey. Journal of Patient-Reported Outcomes, 5(1), Article 66.","journal-title":"Journal of Patient-Reported Outcomes"},{"key":"4184_CR34","volume-title":"How to Score Version 2 of the SF-36\u00ae Health Survey","author":"J Ware","year":"2000","unstructured":"Ware, J., Kosinski, M. A., & Dewey, J. (2000). How to Score Version 2 of the SF-36\u00ae Health Survey. Lincoln."},{"key":"4184_CR35","unstructured":"Team, R. C. (2024). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria."},{"issue":"3","key":"4184_CR36","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s10689-008-9182-z","volume":"7","author":"JG Reichelt","year":"2008","unstructured":"Reichelt, J. G., M\u00f8ller, P., Heimdal, K., & Dahl, A. A. (2008). Psychological and cancer-specific distress at 18 months post-testing in women with demonstrated BRCA1 mutations for hereditary breast\/ovarian cancer. Familial Cancer, 7(3), 245\u2013254.","journal-title":"Familial Cancer"},{"issue":"32","key":"4184_CR37","doi-asserted-by":"publisher","first-page":"4302","DOI":"10.1200\/JCO.2010.33.1561","volume":"29","author":"CH Halbert","year":"2011","unstructured":"Halbert, C. H., Stopfer, J. E., McDonald, J., Weathers, B., Collier, A., Troxel, A. B., & Domchek, S. (2011). Long-term reactions to genetic testing for BRCA1 and BRCA2 mutations: Does time heal women\u2019s concerns? Journal of Clinical Oncology, 29(32), 4302\u20134306.","journal-title":"Journal of Clinical Oncology"},{"issue":"20","key":"4184_CR38","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1200\/JCO.2003.10.100","volume":"21","author":"I van Oostrom","year":"2003","unstructured":"van Oostrom, I., Meijers-Heijboer, H., Lodder, L. N., Duivenvoorden, H. J., van Gool, A. R., Seynaeve, C., & Tibben, A. (2003). Long-term psychological impact of carrying a BRCA1\/2 mutation and prophylactic surgery: A 5-year follow-up study. Journal of Clinical Oncology, 21(20), 3867\u20133874.","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"4184_CR39","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/pon.3039","volume":"22","author":"M den Heijer","year":"2013","unstructured":"den Heijer, M., Seynaeve, C., Vanheusden, K., Timman, R., Duivenvoorden, H. J., Tilanus-Linthorst, M., & Tibben, A. (2013). Long-term psychological distress in women at risk for hereditary breast cancer adhering to regular surveillance: A risk profile. Psycho-Oncology, 22(3), 598\u2013604.","journal-title":"Psycho-Oncology"},{"issue":"2","key":"4184_CR40","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/gim.2015.50","volume":"18","author":"MR Wevers","year":"2016","unstructured":"Wevers, M. R., Ausems, M. G., Verhoef, S., Bleiker, E., Hahn, D. E., Brouwer, T., & Aaronson, N. K. (2016). Does rapid genetic counseling and testing in newly diagnosed breast cancer patients cause additional psychosocial distress? results from a randomized clinical trial. Genetics in Medicine, 18(2), 137\u2013144.","journal-title":"Genetics in Medicine"},{"issue":"2","key":"4184_CR41","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10689-004-7995-y","volume":"4","author":"A Geirdal","year":"2005","unstructured":"Geirdal, A., Reichelt, J. G., Dahl, A. A., Heimdal, K., M\u00e6hle, L., Stormorken, A., & M\u00f8ller, P. (2005). Psychological distress in women at risk of hereditary breast\/ovarian or HNPCC cancers in the absence of demonstrated mutations. Familial Cancer, 4(2), 121\u2013126.","journal-title":"Familial Cancer"},{"issue":"1","key":"4184_CR42","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1897-4287-11-14","volume":"11","author":"L Macrae","year":"2013","unstructured":"Macrae, L., de Souza, A. N., Loiselle, C. G., & Wong, N. (2013). Experience of BRCA1\/2 mutation-negative young women from families with hereditary breast and ovarian cancer: A qualitative study. Hereditary Cancer in Clinical Practice, 11(1), 14.","journal-title":"Hereditary Cancer in Clinical Practice"}],"container-title":["Quality of Life Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-026-04184-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11136-026-04184-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-026-04184-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:09:20Z","timestamp":1781633360000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11136-026-04184-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4184"],"URL":"https:\/\/doi.org\/10.1007\/s11136-026-04184-1","relation":{},"ISSN":["0962-9343","1573-2649"],"issn-type":[{"value":"0962-9343","type":"print"},{"value":"1573-2649","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"assertion":[{"value":"1 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Y.H. has received honoraria for lectures from AstraZeneca. H.R., C.H., B.N.H., and A.R. declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Written informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"This manuscript does not contain any individual person\u2019s data in any form.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The study was approved by the Swedish Ethical Review Authority (Dnr 2019\u201302647, June 19, 2019), with subsequent amendments approved under Dnr 2020\u201301176 (May 18, 2020), Dnr 2021\u201300718 (March 11, 2021), and Dnr 2021\u201305890 (December 15, 2021). Data were de-identified prior to analysis, and the study was conducted in accordance with the principles of the Declaration of Helsinki.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"70"}}